|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.444 EUR | -0.06% |
|
-5.95% | -27.03% |
| Apr. 11 | Valneva: Deep Track Biotechnology Master holds less than 5% of the capital | CF |
| Mar. 26 | Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate | MT |
(Reuters) - French biotech company Valneva on Wednesday raised its product sales guidance and said it now expects revenues of between 170 million euros and 190 million euros ($184.72 million to $206.45 million) in 2024, as it anticipates sales growth of its travel vaccines and the launch of Ixiaro.
It now expect product sales for the year of between 160 million euros and 180 million euros.
In 2023, Valneva saw its total revenues drop to 153.7 million euros from 361.3 million euros a year earlier, missing a LSEG estimate of 171.7 million euros.
Valneva's product sales grew to 144.6 million euros from 114.8 million euros in 2023, a 63% rise excluding COVID-19 vaccine sales, it said in a statement.
(Reporting by Dagmarah Mackos; Editing by Jamie Freed)
| 1st Jan change | Capi. | |
|---|---|---|
| -27.03% | 510M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
VALNEVA 
